Drugs / BBO-11818
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06917079 | Mar 2025 → Aug 2027 expected | colorectal cancer, non-small cell lung carcinoma, pancreatic ductal adenocarcinoma | TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 6
| Date | Issuer | Release |
|---|---|---|
| 2026-04-22 | TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) | Results BBOT Presents Preclinical Data Demonstrating pan-KRAS Inhibitor BBO-11818 Has Robust Anti-Tumor Activity in KRAS-Mutant Preclinical Models at the AACR Annual Meeting 2026 bbotx.com ↗
The data underscore BBO-11818’s differentiated activity across multiple KRAS-mutant cancer types. |
| 2026-04-20 | TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) | Regulatory BBOT Granted U.S. FDA Fast Track Designation for BBO-11818 for the Treatment of Adult Patients with Advanced KRAS-Mutant Pancreatic Ductal Adenocarcinoma bbotx.com ↗ |
| 2026-03-06 | TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) | Results BBOT Announces Publication in Cancer Discovery Highlighting Preclinical Data Demonstrating BBO-11818 is a Potent and Selective panKRAS Inhibitor bbotx.com ↗
BBO-11818 showed significant tumor growth inhibition across multiple tumor types in preclinical models and demonstrated enhanced efficacy in combination with other anti-tumor agents, including BBO-10203, BBOT’s selective RAS:PI3Kα breaker |
| 2026-01-07 | TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) | Results BBOT Announces New Clinical Data Advancing Its Portfolio of Three Innovative and Differentiated RAS and PI3Kα Pipeline Programs bbotx.com ↗
BBO-11818 monotherapy demonstrated a confirmed partial response (PR) in pancreatic cancer and anti-tumor activity was observed across dose levels and tumor types with tumor reductions at higher dose levels with a generally favorable, differentiated safety profile in dose escalation. |
| 2025-10-23 | TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) | Results BBOT Presents Preclinical Data Demonstrating Potential of BBO-11818 as a Potent panKRAS Inhibitor at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics bbotx.com ↗
today announced new preclinical data on BBO-11818 demonstrating its potential as a potent panKRAS inhibitor targeting mutant KRAS in both the ON (active GTP-bound) and OFF (inactive GDP-bound) states, with selectivity over HRAS and NRAS. |
| 2025-10-13 | TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) | Results BBOT Announces Poster Presentations at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics bbotx.com ↗
BBO-11818: an orally bioavailable, highly potent and selective non-covalent pan-KRAS(ON) and (OFF) inhibitor with robust anti-tumor activity in KRAS-mutant preclinical models |
All press releases naming this drug 8 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BBO-11818 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06917079 ↗ |
| Action | Inhibit | “BBO-11818, a potent, selective, orally bioavailable noncovalent pan-KRAS inhibitor capable of targeting multiple KRAS mutants” PMID 41790032 ↗ Apr 2026 |
| Route | Oral | “Participants will receive assigned dose of BBO-11818 orally (PO)” NCT06917079 ↗ |
| Target | KRAS | “We discovered BBO-11818, a potent, selective, orally bioavailable noncovalent pan-KRAS inhibitor capable of targeting multiple KRAS mutants in both the inactive GDP-bound (OFF)...” PMID 41790032 ↗ Apr 2026 |